



ASX Release

Adherium enters into short-term loan funding facility

Melbourne, Australia – 29 June 2026: Adherium Limited (ASX:ADR) (“Adherium” or “the Company”), a global leader in digital respiratory management and developer of the US FDA-cleared Hailie® Smartinhaler® has received funding of USD\$1.65 million via a short-term unsecured loan funding facility (“Loan Facility”) from its major shareholder, Trudell Medical Limited (“Trudell”), a global leader in aerosol drug delivery and lung health devices from the management of respiratory conditions. The Loan Facility will provide funding for working capital requirements.

Details of Loan Facility

The material terms of the Loan Facility are:

Loan Amount	The principal amount is USD\$1.65 million.
Interest	Interest will be charged on the principal amount at 12% per annum with interest capitalised monthly until repayment.
Repayment	<p>The loan repayment date is 30 September 2026 unless Trudell and Adherium mutually agree to extend the repayment date on a month to month basis.</p> <p>Adherium may repay the Loan Facility at any time prior to the repayment date without penalty.</p> <p>The Loan Facility will become immediately repayable where there is an event of default.</p>
Security	The Loan Facility is unsecured.

Consideration of the Board

The Company has chosen to obtain the Loan Facility from Trudell, rather than from an unrelated party, because alternative funding options (such as from third-party financiers), are limited, uncertain, or available only on terms that are materially less favourable to the Company on the basis that:

- the Loan Facility does not dilute existing shareholders;
- the interest rate is considered to be reasonable in the circumstances;



ASX Release

- the ability to quickly execute the Loan Facility as opposed to alternative funding options; and
- the funding available from Trudell is able to meet immediate working capital requirements while the Company seeks approval to implement a more appropriate capital structure through a share consolidation (as announced on 21 May 2026) and explores R&D lending opportunities.

The Board (with Mr George Baran who is associated with Trudell abstaining) considers that the terms of the Loan Facility have been negotiated on arm's length terms, being on comparable terms to similar short term loans with unrelated parties, and therefore does not require shareholder approval under Part 2.E of the *Corporations Act 2001* (Cth).

Learn more at adherium.com

This ASX announcement was approved and authorised for release by the Board of Adherium.

- ENDS -

Investor Enquiries

Adherium Limited
investors@adherium.com

Media Enquiries:

Haley Chartres
HACK Director
haley@hck.digital

About Adherium (ASX: ADR):

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie[®] platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management. The Hailie[®] solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie[®] solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease. Learn more at adherium.com